GOALS - The process of conversion of a normal cell to a malignant cell is, in almost all instances, a multistep process which involves the subversion or alteration of normal cellular and molecular processes that regulate cell growth and differentiation to abnormal process which play a direct role in loss of growth control and/or differentiation. Recent advances in molecular biology have led to the identification and characterization of several of the important components of normal growth and differentiation pathways in many different cell types representing all three germ lines. i.e. tissues from endoderm, mesoderm and ectoderm. In several instances these processes are unique to a given cell or tissue type while in others they appear to be more generic and similar if not identical across multiple cell and tissue types. Recent data indicate that one of the important processes which shares many similarities between different cell types is the process of signal transduction beginning with activation of cell surface receptors by cognate ligands, to the transfer of the surface signal to cytoplasmic signaling molecules to the ultimate transduction of the signal into the nucleus with the resultant transcription of specific genes leading to cell growth or differentiation. The overall goal of this Program Project is to study component parts of this process in a series of relevant mammalian cell systems with the hope of gaining greater insights into both the normal and abnormal function of the molecular events which occur. Interaction among and between the individual projects of this program will lead to enhancement of our knowledge of primary, secondary and tertiary effectors in the signal transduction pathway(s) under study. Such information should prove important in understanding the molecular pathogenesis of a number of human malignancies and may well lead to the development of new diagnostic and therapeutic approaches to these diseases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA032737-17
Application #
2894543
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Program Officer
Freeman, Colette S
Project Start
1982-04-01
Project End
2002-05-31
Budget Start
1999-07-22
Budget End
2002-05-31
Support Year
17
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
O'Brien, Neil A; McDonald, Karen; Tong, Luo et al. (2014) Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res 20:3507-20
Short, John D; Dere, Ruhee; Houston, Kevin D et al. (2010) AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability. Mol Carcinog 49:429-39
Klichko, Yaroslav; Liong, Monty; Choi, Eunshil et al. (2009) Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. J Am Ceram Soc 92:s2-s10
Lu, Jie; Chan, Lai; Fiji, Hannah D G et al. (2009) In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol Cancer Ther 8:1218-26
Short, John D; Houston, Kevin D; Dere, Ruhee et al. (2008) AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Res 68:6496-506
Lu, Jie; Choi, Eunshil; Tamanoi, Fuyuhiko et al. (2008) Light-activated nanoimpeller-controlled drug release in cancer cells. Small 4:421-6
Liong, Monty; Lu, Jie; Kovochich, Michael et al. (2008) Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2:889-96
Watanabe, Masaru; Fiji, Hannah D G; Guo, Lea et al. (2008) Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem 283:9571-9
Lu, Jie; Liong, Monty; Sherman, Sean et al. (2007) Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Nanobiotechnology 3:89-95
Lu, Jie; Liong, Monty; Zink, Jeffrey I et al. (2007) Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3:1341-6

Showing the most recent 10 out of 213 publications